Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Recurrent Meningioma: early-phase trial registry

6 of 7 indexed Recurrent Meningioma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Recurrent Meningioma: 7 US clinical trials tracked, 6 recruiting.

Recurrent Meningioma is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition recurrent-meningioma

OPEN 6 | RECR 86% | LATE 0 | EARLY 6 | RANK #2497 | SPON 1

Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)

Recurrent Meningioma (this)86%ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Recurrent Meningioma

Recurrent Meningioma lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Meningioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Meningioma is recruiting above its size-band peers.

    6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Recurrent Meningioma trials is spread across many organizations.

    Alliance for Clinical Trials in Oncology accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Meningioma trials plan to enrol fewer than 100 people.

    Median target enrolment is 37 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Recurrent Meningioma research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4

Named interventions

Most-linked intervention names on Recurrent Meningioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Gallium Ga 68-DOTATATE Radiation
2 trials
Echocardiography Test Procedure
2 trials
Magnetic Resonance Imaging Procedure
2 trials
Biospecimen Collection Procedure
2 trials
Actinium Ac 225 DOTATATE RYZ101 Drug
1 trials
Hypofractionated Stereotactic Radiosurgery (SRS) Radiation
1 trials
NovoTTF-200A Device Device
1 trials
Electric Field Therapy Procedure
1 trials

US sites by state

Facility locations filed on Recurrent Meningioma trials. A trial with sites in several states counts in each.

California 5 trials
Minnesota 2 trials
Florida 2 trials
Arizona 2 trials
Pennsylvania 1 trials
Ohio 1 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Meningioma page

7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Meningioma condition card totals 7 registered trials; most-linked intervention Gallium Ga 68-DOTATATE; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.